Comparative Pharmacology
Head-to-head clinical analysis: DROXIA versus LONSURF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROXIA versus LONSURF.
DROXIA vs LONSURF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyurea inhibits ribonucleotide reductase, depleting deoxyribonucleotides and inducing fetal hemoglobin (HbF) synthesis.
LONSURF (trifluridine and tipiracil) is a combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil. Trifluridine incorporates into DNA and inhibits cell proliferation, while tipiracil increases trifluridine exposure by inhibiting its degradation by thymidine phosphorylase.
Hydroxyurea (Drosia) for sickle cell anemia: Oral, starting dose 15 mg/kg once daily; escalate by 5 mg/kg every 12 weeks to maximum 35 mg/kg/day. For essential thrombocythemia: 15-30 mg/kg once daily. For myelodysplastic syndrome: 15-30 mg/kg once daily.
Adults: 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle.
None Documented
None Documented
3–4 hours in patients with normal renal function; prolonged to 8–12 hours in moderate to severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Trifluridine: terminal half-life approximately 1.4-2.1 hours; tipiracil: terminal half-life approximately 2-3 hours. Clinical context: short half-lives necessitate twice-daily dosing on Days 1-5 and 8-12 of a 28-day cycle.
Renal: approximately 50% of absorbed dose excreted unchanged in urine. Biliary/fecal: up to 20% excreted in feces as metabolites, with less than 5% as unchanged drug.
Primarily renal: tipiracil is excreted unchanged in urine (approximately 50% of dose); trifluridine is eliminated via metabolism and renal excretion (as metabolites and unchanged drug). Fecal elimination accounts for <3% of total clearance.
Category C
Category C
Antineoplastic
Antineoplastic